ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer

Not Applicable

Completed

Conditions: Soft Tissue Sarcoma
Malignant Neoplasm
Ovarian Neoplasm
Breast Carcinoma
Colon Carcinoma
Kidney Neoplasm
Lung Carcinoma
Melanoma
Adult Liver Carcinoma
Malignant Head and Neck Neoplasm

Interventions: Procedure: Hyperthermia Treatment
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-11

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01896778

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

Not Applicable

Completed

Conditions: Stage IV Renal Cell Cancer
Recurrent Renal Cell Cancer

Interventions: Radiation: stereotactic body radiation therapy
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2013-07-08

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01892930

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

Not Applicable

Completed

Conditions: Recurrent Melanoma
Stage IA Skin Melanoma
Stage IB Skin Melanoma
Stage IIA Skin Melanoma
Stage IIB Skin Melanoma
Stage IIC Skin Melanoma
Stage IIIB Skin Melanoma
Stage IV Skin Melanoma
Stage IIIA Skin Melanoma
Stage IIIC Skin Melanoma

Interventions: Procedure: Diagnostic Microscopy
Drug: Fluorescein Sodium Injection
Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2013-06-25

Last Posted Date: 2020-08-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01886235

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Small Cell Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pegylated Irinotecan
Other: Pharmacological Study

First Posted Date: 2013-06-12

Last Posted Date: 2020-03-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01876446

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Linden Oaks Medical Campus, Rochester, New York, United States
🇺🇸
Rochester General Hospital, Rochester, New York, United States

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 1

Completed

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIB Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer

Interventions: Drug: Temoporfin
Procedure: Therapeutic Conventional Surgery
Drug: Photodynamic Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2013-05-15

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01854684

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Advanced Adult Hepatocellular Carcinoma
Non-Resectable Hepatocellular Carcinoma

Interventions: Drug: Tivozanib (1.5mg)
Drug: Tivozanib (1mg)

First Posted Date: 2013-04-18

Last Posted Date: 2020-10-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 33

Registration Number: NCT01835223

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Alkylating Agent-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Refractory Anemia With Excess Blasts in Transformation

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Drug: Poly ICLC

First Posted Date: 2013-04-17

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01834248

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Not Applicable

Completed

Conditions: Recurrent Prostate Carcinoma
Stage IV Prostate Cancer
Metastatic Malignant Neoplasm in the Bone
Hormone-Resistant Prostate Cancer

Interventions: Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy

First Posted Date: 2013-04-16

Last Posted Date: 2021-08-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01833208

Locations: 🇺🇸
Western New York Urology Associates LLC-Harlem, Cheektowaga, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers

Not Applicable

Terminated

Conditions: Tobacco Use Disorder

Interventions: Behavioral: smoking cessation intervention
Other: questionnaire administration
Other: quality-of-life assessment
Other: laboratory biomarker analysis
Other: ecigarettes

First Posted Date: 2013-02-27

Last Posted Date: 2022-09-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 72

Registration Number: NCT01800500

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Early Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Combination Product: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
Other: quality-of-life assessment

First Posted Date: 2013-02-01

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01781741

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy